Abstract:Juan Chen, 1, &ast Qiqiang Liang, 1, &ast Shuo Ding, 1 Yongshan Xu, 1 Yanting Hu, 1 Jingyu Chen, 2, 3 Man Huang 1, 3 1 Department of General Intensive Care Unit, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China; 2 Wuxi Lung Transplant Center, Wuxi People's Hospital affiliated to Nanjing Medical University, Wuxi, Jiangsu, People's Republic of China; 3 Department of Lung Transplantation, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Man Huang, Department of General Intensive Care Unit, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China, Tel/Fax +86 571 89713427, Email Jingyu Chen, Wuxi Lung Transplant Center, Wuxi People's Hospital affiliated to Nanjing Medical University, Wuxi, Jiangsu, People's Republic of China, Email Background: Experience of ceftazidime-avibactam (CAZ/AVI) for carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection in recipients after lung transplantation (LT) is relatively limited. Methods: A retrospective observational study was conducted on lung transplant recipients receiving CAZ/AVI therapy for CRPA infection. The primary outcomes were the 14-day and 30-day mortality. The secondary outcomes were clinical cure and microbiological cure. Results: Among 183 LT recipients, a total of 15 recipients with CRPA infection who received CAZ/AVI therapy were enrolled in this study. The mean age of recipients was 54 years and 73.3% of recipients were male. The median time from infection onset to initiation of CAZ/AVI treatment was 4 days (IQR, 3– 7) and the mean duration of CAZ/AVI therapy was 10 days. CAZ/AVI was mainly administered as monotherapy in LT recipients (80%). Among these eligible recipients, 14-day and 30-day mortality were 6.7% and 13.3%, respectively. The clinical cure and microbiological cure rates of CAZ/AVI therapy were 53.3% and 60%, respectively. Three recipients (20%) experienced recurrent infection. In addition, the mean lengths of ICU stay and hospital stay were 24 days and 35 days, respectively, among LT recipients. Conclusion: CAZ/AVI may be an alternative and promising regimen for CRPA eradiation in lung transplant recipients. Keywords: carbapenem-resistant Pseudomonas aeruginosa , ceftazidime/avibactam, lung transplantation, infection, efficacy, mortality Lung transplantation is currently the only therapeutic option for selected patients with end-stage pulmonary disease. 1 Although survival among patients with lung transplantation has been improved over time, 2 the long-term survival after transplantation is limited. 3 It was reported that the 5-year survival after transplantation was about 60% worldwide. 3–5 Notably, within the first year after transplantation, infection is one of the two leading causes of death. 4,6,7 Unlike other common organ transplants, lung transplant has a high risk of infection because the lung allograft as an essential component of airway is in direct contact with environment outside, leading to the invasion of microorganisms. Besides, transplantation recipients are exposed to risk factors of infection, including the use of immunosuppressive agents, such as tacrolimus, more invasive operations, and prolonged ICU stay. 8,9 Therefore, the incidence of infection and colonization after lung transplantation increased, including a variety of multidrug-resistant (MDR) bacterial infections. It was reported that infections were frequent with high incidence among 2761 recipients of solid organ transplant (SOT), and bacteria predominated, including Enterobacteriaceae, Pseudomonas aeruginosa (PA), and Enterococcus spp. 10 Importantly, P. aeruginosa was the major bacterial pathogens identified in proven infections of lung transplant. 10 Almost 50% of P. aeruginosa bloodstream infections were caused by MDR strains. 8 In a prospective observational study of Spain, among P. aeruginosa bacteremia of SOT recipients, 63% of bacteremia caused by extensively drug-resistant (XDR) P. aeruginosa . 11 Meanwhile, in transplant recipients, the incidence of infections caused by MDR/XDR P. aeruginosa was higher than in the general population. 8,12,13 Notably, MDR P. aeruginosa infection was related with high mortality in case of bacteremia among SOT recipients -Abstract Truncated-

Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime–avibactam

A case of pan-resistant Burkholderia cepacia complex bacteremic pneumonia, after lung transplantation treated with a targeted combination therapy

Successful ceftazidime‐avibactam treatment of post‐surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis

Clinical Outcomes of Ceftazidime-Avibactam in Lung Transplant Recipients with Infections Caused by Extensively Drug-Resistant Gram-Negative Bacilli

Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients

Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant <i>Pseudomonas</i> aeruginosa Infection

Burkholderia cepacia complex in cystic fibrosis: critical gaps in diagnosis and therapy

Bacterial Re-Colonization Occurs Early after Lung Transplantation in Cystic Fibrosis Patients

Susceptibility of Burkholderia cepacia Complex to Ceftazidime/Avibactam and Standard Drugs of Treatment for Cystic Fibrosis Patients.

Outcomes of non-cystic fibrosis-related bronchiectasis post-lung transplantation

Management of superior vena cava syndrome during lung transplantation for a patient with cystic fibrosis

Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam

Survival After Lung Transplant for Cystic Fibrosis in Portugal: A Single Center Experience

Ceftazidime-avibactam treatment dilemma of blaKPC−2-containing Klebsiella pneumoniae due to the development of co-existence of mixed strains carrying blaKPC−2 or blaKPC−33 in lung transplant recipients

Bridging Echinocandin With Azole Antifungal Therapy on Prevention of Invasive Candidiasis Post-Lung Transplantation

Cefiderocol utilization in lung transplant recipients at a single center

Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan‐drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient

Safety and tolerability of bronchoscopic and nebulised administration of bacteriophage

40-year single center experience of Burkholderia cystic fibrosis airway infections

Early clinical experience of bacteriophage therapy in 3 lung transplant recipients

Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae